NASDAQ GS | VYGR (Common Stock)

$12.40

 0.06 (0.48%)

Data as of: 02/22/17  11:31 a.m. ET

Investor Overview

Webcast ImageWebcast
Voyager Therapeutics, Inc. at LEERINK Partners 6th Annual Global Healthcare Conference (Replay)
02/15/17 at 11:30 a.m. ET
Voyager Therapeutics, Inc. at LEERINK Partners 6th Annual Global Healthcare Conference
Wednesday, February 15, 2017 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. More >>

Recent NewsMore >>
February 13, 2017
Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)
February 02, 2017
Voyager Therapeutics to Attend Upcoming Investor Conferences
January 25, 2017
Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience
Upcoming EventsMore >>
DateTitle
03/06/17 4:40 p.m. ET
Voyager Therapeutics Inc at Cowen and Company 37th Annual Health Care Conference, Boston
Data provided by Nasdaq. Minimum 15 minutes delayed.